A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

Stopped The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.

Conditions

• Ulcerative Colitis

Interventions

• DRUG: Mirikizumab IV
• DRUG: Mirikizumab SC
• DRUG: Vedolizumab IV
• DRUG: Placebo IV
• DRUG: Placebo SC

Sponsor

Eli Lilly and Company